EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench

Xin Chen iD, Carl-Friedrich Hocher, Linghong Shen, Bernhard K Krämer, Berthold Hocher iD

American Journal of Physiology-Cell Physiology · 2023

DOI: 10.1152/ajpcell.00177.2023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Physiology-Cell Physiology, 2023. Verfasst von Xin Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Charité-Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 230 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Large placebo-controlled clinical trials have shown that sodium-glucose cotransporter-2 inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular events in a glucose-independent manner, thereby ultimately reducing mortality in patients with chronic kidney disease (CKD) and/or heart failure. These existing clinical data stimulated preclinical studies aiming to understand the observed clinical effects. In animal models, it was shown that the beneficial effect of SGLT2i on the tubuloglomerular feedback (TGF) improves glomerular pressure and reduces tubular workload by improving renal hemodynamics, which appears to be dependent on salt intake. High salt intake might blunt the SGLT2i effects on the TGF. Beyond the salt-dependent effects of SGLT2i on renal hemodynamics, SGLT2i inhibited several key aspects of macrophage-mediated renal inflammation and fibrosis, including inhibiting the differentiation of monocytes to macrophages, promoting the polarization of macrophages from a proinflammatory M1 phenotype to an anti-inflammatory M2 phenotype, and suppressing the activation of inflammasomes and major proinflammatory factors. As macrophages are also important cells mediating atherosclerosis and myocardial remodeling after injury, the inhibitory effects of SGLT2i on macrophage differentiation and inflammatory responses may also play a role in stabilizing atherosclerotic plaques and ameliorating myocardial inflammation and fibrosis. Recent studies suggest that SGLT2i may also act directly on the Na + /H + exchanger and Late-I Na in cardiomyocytes thus reducing Na + and Ca 2+ overload-mediated myocardial damage. In addition, the renal-cardioprotective mechanisms of SGLT2i include systemic effects on the sympathetic nervous system, blood volume, salt excretion, and energy metabolism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsAnimalsFibrosisInflammationKidneySodium Chloride, Dietary

Stichwörter der Autor:innen

cardiorenal protectionmacrophage polarizationnondiabetic CKDsodium-glucose cotransporter-2 inhibitorstubuloglomerular feedback

Substanzen

Sodium Chloride, DietarySodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Nephrology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany.
  • Klinik für Innere Medizin, Bundeswehrkrankenhaus Berlin, Berlin, Germany.
  • Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, China.
  • Institute of Reproductive and Stem Cell Engineering, NHC Key Laboratory of Human Stem Cell and Reproductive Engineering, School of Basic Medical Science, Central South University, Changsha, China.

ORCID-Profile: Xin Chen, Berthold Hocher

Zitieren

APA

Chen, X., Hocher, C. F., Shen, L., Krämer, B. K., & Hocher, B. (2023). Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.00177.2023

Vancouver

Chen X, Hocher CF, Shen L, Krämer BK, Hocher B. Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench. American Journal of Physiology-Cell Physiology. 2023. doi:10.1152/ajpcell.00177.2023

BibTeX
@article{Chen2023,
  author = {Chen, Xin and Hocher, Carl-Friedrich and Shen, Linghong and Krämer, Bernhard K and Hocher, Berthold},
  title = {Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench},
  journal = {American Journal of Physiology-Cell Physiology},
  year = {2023},
  doi = {10.1152/ajpcell.00177.2023}
}
Kostenlos starten →